Common TitleSURVEYOR-II (Part 4)
Official Title Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients with HCV Genotype 2, 4, 5, or 6 Infection Without Cirrhosis.
Phase Phase III
ClinicalTrials.gov NCT02243293
Treatments
Glecaprevir-Pibrentasvir
Glecaprevir-Pibrentasvir
Tradename:MavyretOther Names:GLE-PIBClass:FDA-ApprovedFunding
IndustryAbbVie
